NUREXONE BIOLOGIC INC (NRX.CA) Stock Income Statement
Canada - TSX Venture Exchange - TSX-V:NRX - CA67059R1091 - Common Stock
0.65 CAD
+0.03 (+4.84%)
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 6.47M | 5.01M | 3.66M | 5.54M | 130.00K | |||
| Research and Development | 2.65M | 1.83M | 1.53M | 1.39M | 0.00 | |||
| Selling, General, and Administrative Expenses | 3.82M | 3.11M | 2.10M | 4.14M | 130.00K | |||
| Operating Income | -6.47M | -5.01M | -3.66M | -5.54M | -130.00K | |||
| Interest Income/Expense | -63.00K | -34.00K | 18.00K | -550.00K | N/A | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | 0.00 | |||
| Non Recurring Items | N/A | N/A | 0.00 | -2.08M | N/A | |||
| Income Before Taxes | -6.54M | -5.04M | -3.64M | -8.17M | -130.00K | |||
| Net Income | -6.54M | -5.04M | -3.64M | -8.17M | -130.00K | |||
| EBITDA | -6.30M | -4.92M | -3.62M | -5.54M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.09 | -0.08 | -0.08 | -0.22 | -0.05 | |||
| Non GAAP EPS | -0.09 | N/A | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD